IgA Nephropathy (IgAN), also known as Berger’s disease, is a kidney disease that occurs when IgA deposits build up in the kidneys, causing inflammation that damages kidney tissues. IgA is an antibody which is a protein made by the immune system to protect the body from foreign substances such as bacteria or viruses.
IgA nephropathy affects the kidneys by attacking the glomeruli. The glomeruli are sets of looping blood vessels in nephrons which is the tiny working units of the kidneys that filter wastes and remove extra fluid from the blood. The buildup of IgA deposits inflames and damages the glomeruli, causing the kidneys to leak blood and protein into the urine. The damage may lead to scarring of the nephrons that progresses slowly over many years. Eventually, IgA nephropathy can lead to End‐stage Renal Disease (ESRD). Which means the kidneys no longer work well enough to keep a person healthy.
In its early stages, IgA nephropathy may have no symptoms; it can be silent for years or even decades. Once symptoms appear, the most common one is hematuria. Hematuria can be a sign of damaged glomeruli. Another symptom of IgA nephropathy is albuminuria.
After 10 to 20 years with IgA nephropathy, about 20 to 40 per cent of adults develop end‐stage kidney disease. Signs and symptoms of end‐stage kidney disease may include high blood pressure, edema, drowsiness, dry skin, appetite loss, nausea, vomiting, sleep problems, trouble concentrating, darkened skin, muscle cramps etc.
There are several factors that lead to IgA nephropathy progression and limit the patient’s life expectancy. These include disease progression as well as some other disease factors, such as diabetes, hypertension, and cardiovascular‐related lifestyle conditions.
The DelveInsight IgA Nephropathy epidemiology report gives a thorough understanding of the IgA Nephropathy by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis.
It also provides treatment algorithms and treatment guidelines for IgA Nephropathy in the US, Europe, and Japan. The report covers the detailed information of the IgA Nephropathy epidemiology scenario in seven major countries (US, EU5, and Japan).
Key Highlights Of The Report
As per the study conducted by Lafayette et al. IgA Immunoglobulin A (IgA) nephropathy is the most common form of primary glomerulonephritis, with a global incidence of at least 2.5 per 100,000 per year in adults.
As per the American Kidney Fund, about one in every four adults with IgA nephropathy eventually gets kidney failure/End‐Stage Renal Disease (ESRD). Approximately, one in every 10–20 children gets kidney failure/End‐stage Renal Disease (ESRD) because of IgA nephropathy.
In a study titled “Race/ethnicity and disease severity in IgA nephropathy”, conducted by Hall et al., IgA nephropathy is the most common form of glomerulonephritis (GN) worldwide. Approximately 20– 30% of individuals with IgA Neuropathy develop the end‐stage renal disease (ESRD) by 10–20 years following diagnosis.
A study was conducted in France by Occelli et al., titled “Mapping End‐Stage Renal Disease (ESRD): Spatial Variations on Small Area Level in Northern France, and Association with Deprivation” that revealed that there are significant geographic differences in ESRD incidence.
Request for Sample Pages:
Delveinsight’s IgA Nephropathy epidemiology division provides insights about historical and current patient pool and forecasted trends for every seven major countries.
The IgA Nephropathy epidemiology data are studied through all possible divisions to give a better understanding of the Disease scenario in 7MM.
The IgA Nephropathy epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030.
It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
Scope of the Report
The report provides insight into the historical and forecasted patient pool of IgA Nephropathy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
The report assesses the disease risk and burden and highlights the unmet needs of IgA Nephropathy.
The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
The IgA Nephropathy report provides a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.
The IgA Nephropathy Epidemiology Report and Model provide an overview of the risk factors and global trends of IgA Nephropathy in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan).
The report provides the segmentation of the IgA Nephropathy epidemiology.
Key Questions Covered In The IgA Nephropathy Report Include:
What will be the growth opportunities in the 7MM with respect to the patient population pertaining to IgA Nephropathy?
What are the key findings pertaining to the IgA Nephropathy epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
What would be the total number of patients of IgA Nephropathy across the 7MM during the forecast period (2017-2030)?
Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
What is the disease risk, burden and unmet needs of the IgA Nephropathy?
What are the currently available treatments of IgA Nephropathy?
Key Benefit of IgA Nephropathy Epidemiology Report
The IgA Nephropathy Epidemiology report will allow the user to –
Develop business strategies by understanding the trends shaping and driving the global IgA Nephropathy market.
Quantify patient populations in the global IgA Nephropathy market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for IgA Nephropathy therapeutics in each of the markets covered.
Understand the magnitude of IgA Nephropathy population by its epidemiology.
The IgA Nephropathy Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources.
Table of Contents
Executive Summary of IgA Nephropathy
IgA Nephropathy Disease Background and Overview
IgA Nephropathy Sign and Symptoms
IgA Nephropathy Pathophysiology
IgA Nephropathy Risk Factors
IgA Nephropathy Diagnosis
IgA Nephropathy Patient Journey
IgA Nephropathy Epidemiology and Patient Population
IgA Nephropathy Treatment Algorithm, Current Treatment, and Medical Practices
KOL Views on IgA Nephropathy
IgA Nephropathy Unmet Needs
*The table of contents is not exhaustive; will be provided in the final report
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
IgA Nephropathy (IgAN) Market Insight, Epidemiology and Market Forecast 2030
DelveInsight’ s IgA Nephropathy (IgAN) Market Insights, Epidemiology and Market Forecast 2030 report provides a detailed overview of the disease and in-depth understanding of historical and forecasted epidemiology.
IgA Nephropathy (IgAN) Pipeline Insights, 2020
IgA Nephropathy (IgAN) Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the IgA Nephropathy (IgAN) market.
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States